...Yu Hashimoto; Syota Tomaru; Yuki Itoi; Keigo Sato; Hiroko Hosaka; Hirohito Tanaka; Shiko Kuribayashi; Yoji Takeuchi; Toshio Uraoka Background: Patients with a long history of ulcerative colitis (UC) are at risk of developing a serious complication known as UC-associated neoplasia (UCAN). Because...

... of moderately to severely active ulcerative colitis (UC). Here, we report the primary analysis of a phase 3 trial evaluating the efficacy and safety of etrasimod in patients from Japan with moderately to severely active UC. Methods: Patients from Japan who completed the 12-week ELEVATE UC 12 induction trial...

...Siyuan Dong; Yu Zhang; Lingna Ye; Qian Cao Introduction: Natural killer (NK) cells are associated with the pathogenesis of ulcerative colitis (UC); however, their precise contributions remain unclear. The present study aimed to investigate the diagnostic value of the activated NK-associated gene...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Ulcerative colitis Somatostatin Biomarkers Disease activity...

... the associations among disease-related symptoms, health-related quality of life (HRQOL), and sense of coherence (SOC) in Japanese patients with ulcerative colitis (UC). Methods: This cross-sectional survey involved patients and physicians at 23 hospitals specializing in UC treatment in Japan (December 2019...

...Takumi Ota; Takahiro Takebe; Yutaka Shimizu; Takashi Orido; Hiroyuki Tanaka; Shiro Nakamura Introduction: 5-aminosalicylic acid (5-ASA) is the first-line drug for the treatment of mild-to-moderate ulcerative colitis (UC). Three oral sustained-release formulations are often used. However, no unified...

...Noriko Yamamoto; Ken Yamashita; Yudai Takehara; Shin Morimoto; Fumiaki Tanino; Yuki Kamigaichi; Hidenori Tanaka; Koji Arihiro; Fumio Shimamoto; Shiro Oka Introduction: Patients with ulcerative colitis (UC) develop not only UC-associated neoplasias but also sporadic neoplasias (SNs). However, few...

..., the prevalence and types of EIMs, which are defined based on previous reports and the Japanese guidelines, were investigated. Results: This cohort enrolled 728 patients, including 542 ulcerative colitis (UC) and 186 Crohn’s disease (CD). Of these patients with IBD, 10.0% were identified with one or more EIMs (57...

...-analysis showed that ulcerative colitis (UC) is a risk factor for cardiovascular disease (CVD). Dyslipidemia is a well-established risk factor for CVD. However, evidence regarding inflammatory bowel disease (IBD), including UC and lipid profiles, is limited. Additionally, no study has assessed...

.... Biomarkers play five major roles in the management of IBD: (1) diagnosing and distinguishing between IBD and non-IBD or ulcerative colitis and Crohn’s disease; (2) predicting treatment response, especially before administrating biologics; (3) monitoring and grasping endoscopic or histological disease...

... surgery (OR = 16.24, 95% CI: 1.70–154.95, p = 0.02) were identified as independent risk factors for fatal complications. Ulcerative colitis Surgery Elderly Postoperative complication Commonly, being elderly or having an advanced age has been identified as an important risk factor...

...Yohei Mikami; Junya Tsunoda; Shohei Suzuki; Ichiro Mizushima; Hiroki Kiyohara; Takanori Kanai Background: Two major types of 5-aminosalicylic acid (5-ASA)-containing preparations, namely, mesalazine/5-ASA and sulfasalazine (SASP), are currently used as first-line therapy for ulcerative colitis...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2022 Inflammatory bowel disease Crohn’s disease Ulcerative colitis Cellular...

... from any ideas, methods, instructions or products referred to in the content or advertisements. 2022 Inflammatory bowel disease Ulcerative colitis Crohn’s disease Regenerative medicine Organoids Inflammatory bowel disease (IBD) consists of two main diseases, ulcerative colitis (UC...

... Higuchi Background and Aims: The calcineurin inhibitor tacrolimus is reportedly effective for moderate/severe ulcerative colitis (UC); however, it is also reportedly associated with nephrotoxicity. We investigated the risk factors for tacrolimus-induced nephrotoxicity and whether renal impairment...

... Nakamura; Kazuhide Higuchi Background and Aims: A considerable number of patients with ulcerative colitis (UC) who initially respond to golimumab (GLM), an anti-TNF-α antibody, gradually lose clinical response. Therapeutic drug monitoring has been proposed to optimize serum anti-TNF-α antibody...

... cause inflammation in patients with ulcerative colitis (UC). Fecal microbiota transplantation (FMT) enables manipulating the microbiota’s composition, but the mechanisms underlying colonization of the posttransplantation microbiota are poorly understood. Methods: In this open-label, nonrandomized study...

...). The results from the LEfSe demonstrated significant bacterial differences among patients but not among methods (online suppl. information 7). [email protected] Microbiome Sampling Brush Ulcerative colitis Mass spectrometry The incidence of ulcerative colitis (UC) has...

... in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Methods: Using data obtained in a prospective, multicenter, observational study (PLANET), we assessed serial changes in a novel biomarker – leucine-rich alpha-2 glycoprotein (LRG) – during ADA treatment for patients with active CD and UC. We...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2021 Crohn’s disease Ulcerative colitis Vaccine-preventable infection Immunization As the immune system of patients with inflammatory...